These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 23881910

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
    Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells S.
    J Acquir Immune Defic Syndr; 2013 Oct 01; 64(2):167-73. PubMed ID: 23797691
    [Abstract] [Full Text] [Related]

  • 4. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
    Andrews E, Glue P, Fang J, Crownover P, Tressler R, Damle B.
    Br J Clin Pharmacol; 2010 Jan 01; 69(1):51-7. PubMed ID: 20078612
    [Abstract] [Full Text] [Related]

  • 5. Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium.
    Matsuzawa T, Kawamura T, Ogawa Y, Takahashi M, Aoki R, Moriishi K, Koyanagi Y, Gatanaga H, Blauvelt A, Shimada S.
    J Invest Dermatol; 2013 Dec 01; 133(12):2803-2805. PubMed ID: 23648547
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.
    Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJ, Mitchnick M, Goldman L, Doyle LA, Muldoon BC, Woolfson AD, Moore JP, Malcolm RK.
    J Control Release; 2011 Dec 10; 156(2):161-9. PubMed ID: 21864598
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
    Waters L, Jackson A, Else L, Rockwood N, Newell S, Back D, Nelson M, Gazzard B, Boffito M.
    Antivir Ther; 2015 Dec 10; 20(2):157-63. PubMed ID: 24963558
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
    Mora-Peris B, Croucher A, Else LJ, Vera JH, Khoo S, Scullard G, Back D, Winston A.
    J Antimicrob Chemother; 2013 Jun 10; 68(6):1348-53. PubMed ID: 23364475
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.
    Chen BA, Panther L, Marzinke MA, Hendrix CW, Hoesley CJ, van der Straten A, Husnik MJ, Soto-Torres L, Nel A, Johnson S, Richardson-Harman N, Rabe LK, Dezzutti CS.
    J Acquir Immune Defic Syndr; 2015 Nov 01; 70(3):242-9. PubMed ID: 26034880
    [Abstract] [Full Text] [Related]

  • 15. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
    Gonzalez-Serna A, McGovern RA, Harrigan PR, Vidal F, Poon AF, Ferrando-Martinez S, Abad MA, Genebat M, Leal M, Ruiz-Mateos E.
    Antimicrob Agents Chemother; 2012 Mar 01; 56(3):1202-7. PubMed ID: 22143533
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. When and how to use maraviroc in HIV-infected patients.
    Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, Pillay D, Rockstroh J, Geretti AM.
    AIDS; 2009 Nov 27; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.